CABIO(688089) 信达证券·2025-02-27 14:23Investment Rating - The investment rating for the company is "Buy" [2] Core Insights - The company reported strong Q4 performance, exceeding previous expectations, with a revenue of 168 million and a year-on-year growth of 41.11% [2][4] - The growth in 2024 is attributed to both domestic and international market drivers, alongside the release of new production capacity [4] - The ongoing acquisition of Ouyisheng Bio is expected to enhance the company's multi-omics business model, leveraging AI for data analysis and clinical applications [4] - The earnings forecast for 2024-2026 indicates an EPS of 0.74, 0.84, and 0.99 yuan, corresponding to P/E ratios of 30X, 27X, and 23X respectively [4] Financial Performance Summary - In 2024, the company achieved a total revenue of 555 million, a year-on-year increase of 25.06%, and a net profit of 124 million, up 36.0% [5] - The gross profit margin is projected to be around 42.2% in 2024, with a net asset return (ROE) of 7.9% [5] - The company’s total revenue is expected to grow to 658 million in 2025 and 777 million in 2026, maintaining a growth rate of approximately 18% [5]